Sign in

CIK 0001858848

  • Non-accelerated filer
  • Smaller reporting company
  • Emerging growth company

Tenaya Therapeutics, Inc.

Sign in to watch
Ticker
TNYA
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
813789973
Phone
+1 415-865-2066
Business address
171 OYSTER POINT BLVD., SUITE 500, SOUTH SAN FRANCISCO, CA, 94080
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$0
in 0 filings

Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Date Insider Transaction Shares Price Value Owned after
2025-03-10 Ali Faraz Chief Executive Officer Sale −3,947 $0.54 $2K 320,514
2025-03-05 COLUMN GROUP III GP, LP 10% owner Purchase +35,714,284 $0.70 $25.0M 49,313,559
2025-03-05 COLUMN GROUP III GP, LP 10% owner Purchase · Series A Warrant (right to buy) +35,714,284 35,714,284
2025-03-05 COLUMN GROUP III GP, LP 10% owner Purchase · Series B Warrant (right to buy) +17,857,142 17,857,142
2025-03-05 GOEDDEL DAVID V Director Purchase +35,714,284 $0.70 $25.0M 49,313,559
2025-03-05 GOEDDEL DAVID V Director Purchase · Series A Warrant (right to buy) +35,714,284 35,714,284
2025-03-05 GOEDDEL DAVID V Director Purchase · Series B Warrant (right to buy) +17,857,142 17,857,142
2025-02-06 Ali Faraz Chief Executive Officer Grant or award +107,500 295,831
2025-02-06 Ali Faraz Chief Executive Officer Grant or award +34,424 330,255
2025-02-06 Ali Faraz Chief Executive Officer Grant or award · Stock Option (Right to buy) +650,000 650,000
2025-02-06 Ali Faraz Chief Executive Officer Returned to the company · Stock Option (Right to Buy) −353,271 0
2025-02-06 Ali Faraz Chief Executive Officer Grant or award · Stock Option (Right to Buy) +353,271 353,271
2025-02-06 Ali Faraz Chief Executive Officer Returned to the company · Stock Option (Right to Buy) −161,214 0
2025-02-06 Ali Faraz Chief Executive Officer Grant or award · Stock Option (Right to Buy) +161,214 161,214
2025-02-06 Ali Faraz Chief Executive Officer Returned to the company · Stock Option (Right to Buy) −401,390 0
2025-02-06 Ali Faraz Chief Executive Officer Grant or award · Stock Option (Right to Buy) +401,390 401,390
2025-01-24 Tingley Whittemore Chief Medical Officer Grant or award +40,000 147,106
2025-01-24 Tingley Whittemore Chief Medical Officer Grant or award +31,676 178,782
2025-01-24 Tingley Whittemore Chief Medical Officer Grant or award · Stock Option (Right to buy) +235,000 235,000
2025-01-24 Tingley Whittemore Chief Medical Officer Returned to the company · Stock Option (Right to Buy) −69,982 0

Page 5 of 12 · 228 trades